

Peptide biologics for effective management of breast cancer and fungal keratitis

PRASANJEET KAUR



KUSUMA SCHOOL OF BIOLOGICAL SCIENCES

INDIAN INSTITUTE OF TECHNOLOGY DELHI

JULY 2025

Indian Institute of Technology Delhi (IITD), New Delhi, 2025

Peptide biologics for effective management of breast cancer and fungal keratitis

by

PRASANJEET KAUR

Kusuma School of Biological Sciences

Submitted

in fulfilment of the requirements of the degree of

DOCTOR OF PHILOSOPHY

to the



INDIAN INSTITUTE OF TECHNOLOGY DELHI

JULY 2025

Guru Granth Sahib

Title: Raag Gauree, Guru Arjan Dev Ji

Page: 293, Line No.: 14

ਸਲੋਕੁ ॥

salok |

ਗਿਆਨ ਅੰਜਨੁ ਗੁਰਿ ਦੀਆ ਅਗਿਆਨ ਅੰਧੇਰ ਬਿਨਾਸੁ ॥

Giaan anjan gur deea agiaan andher binaas |

ਹਰਿ ਕਿਰਪਾ ਤੇ ਸੰਤ ਭੇਟਿਆ ਨਾਨਕ ਮਨਿ ਪਰਗਾਸੁ ॥੧॥

Har kirapaa te sant bhattiaa naanak man paragaas |1|

The Guru has given the healing ointment of spiritual wisdom, and dispelled the darkness of ignorance. By the Lord's Grace, I have met the Saint; O Nanak, my mind is enlightened. ||1||

**This thesis is dedicated to my beloved family,
guide and friends for their unconditional
support, love and motivation**

CERTIFICATE

This is to certify that the thesis entitled **“Peptide biologics for effective management of breast cancer and fungal keratitis”** being submitted by **Ms. Prasanjeet Kaur** to the **Kusuma School of Biological Sciences**, Indian Institute of Technology Delhi, New Delhi for the award of the degree of **“Doctor of Philosophy”** is a record of the bonafide research work carried out by her, prepared under my supervision, in conformity with the rules and regulations of the ‘Indian Institute of Technology Delhi’. The research report and the results present in the thesis have not been submitted to any other University or Institute for the award of any other degree or diploma.

Date: 21st July 2025

Place: New Delhi

Dr. Archana Chugh

Professor

Kusuma School of Biological Sciences,
Indian Institute of Technology Delhi

ACKNOWLEDGEMENTS

This thesis is not just the culmination of my research, it's a journey filled with challenges, discoveries, and immense learning. Along the way, I have been fortunate to receive the support, guidance, and encouragement of many incredible individuals, without whom this work would not have been possible. I am deeply grateful to everyone who played a role in making this work a reality.

*First and foremost, I feel blessed to work under the supervision of **Prof. Archana Chugh**, whose invaluable insights, patience, and encouragement have been instrumental in shaping this research. Her mentorship has not only refined my scientific perspective but has also inspired me to push boundaries and strive for excellence. I have been fortunate to have an advisor who instilled in me the qualities of being a good and independent researcher.*

*Further, I would like to extend my heartfelt gratitude to **Dr. Shikha Yadav, Dr. Sushmita Shah and Dr. Harish Chander**, for providing valuable insights and constructive feedback in carrying out in vivo experiments. Their expertise and keen observations have helped refine my work.*

*I would like to express my sincere appreciation to the **Indian Institute of Technology, Delhi** and the **Kusuma School of Biological Sciences** for providing the resources and an intellectually stimulating environment that nurtured this research. A special note of thanks to the **Central Research Facility at IIT Delhi**, whose advanced infrastructure, state-of-the-art equipment, and technical expertise have been instrumental in carrying out crucial aspects of this research. I would also like to extend my sincere gratitude to the **High-Performance Computational Facility at IIT Delhi**, which provided the computational power necessary for the molecular dynamics simulations and other intensive calculations involved in this research. Heartfelt thanks to the **National Institute of Biologics, Noida**, for providing the necessary facilities and support to carry out the in vivo experiments critical to this research. I am also deeply grateful to the **University Grants Commission (UGC)** for providing financial support through the UGC Fellowship.*

*I am incredibly grateful to my amazing labmates, **Dr. Anupama, Dr. Harsha, Dr. Vivek, Dr. Pankhuri, Dr. Sujithra, Dr. Anjali, Dr. Nirupama, Dr. Manobala, Dr. Saurabh, Dr. Gagandeep, Aditi, Gagan, Malay, Mayank, Shiva, Jyoti** for being my support system through*

every high and low of this journey. From celebrating small victories to navigating setbacks, their encouragement, patience, and unwavering camaraderie have made this experience not just productive but truly memorable. Thank you for the insightful discussions, the laughter that kept me going, and for always having my back when experiments or life didn't go as planned. I couldn't have asked for a better team to share this journey with.

*I would also like to extend my heartfelt gratitude to my incredible batchmates and friends from other labs, **Nidhi, Pragati, Maryam, Ram, Vikas, Rituparna, Dr. Akanksha** who have been a constant source of motivation and support. Whether it was sharing ideas over coffee, helping troubleshoot experiments, or simply being there to listen during challenging times, their presence has made this journey so much more enriching. The friendships we have built, the late-night brainstorming sessions, and the shared struggles and successes have been invaluable. Thank you for making this experience not just about research, but also about growth, laughter, and unforgettable memories.*

*I cannot express enough gratitude to my sister, **Lajpreet Kaur**, whose unwavering support and belief in me have been my greatest source of strength. Through every challenge, she has been my confidant and my biggest cheerleader. I am also incredibly thankful to my wonderful friends, **Prachi, Aruna, Kirti**, who always stood by me. Our shared adventures have been a perfect balance to the demands of research. Thank you for being my support system, for celebrating every little milestone, and for making this journey unforgettable.*

Above all, I am profoundly grateful to my family for their unconditional love, patience, and unwavering support throughout this journey. Their belief in me, even during times when I doubted myself, has been my greatest source of strength. From encouraging words to endless motivation, they have been my anchor through every challenge and success. Their sacrifices, understanding, and constant reassurance have given me the confidence to push forward. This thesis is as much a result of their support as it is of my efforts, and I will always be grateful for their presence in my life.

*Lastly, my deepest gratitude goes to my son, **Hunarpratap Singh Kang**, who came into this world while I was writing this thesis. His arrival brought indescribable joy and renewed purpose to my life. Though an infant, his presence was a silent source of strength, patience, and inspiration as I worked through the final stages of my research.*

*I also extend my heartfelt thanks to my husband, **Harpal Singh Kang**, who has stood by me with unwavering love, patience, and encouragement. Thank you for your endless support, for understanding my dedication to this journey, and for always reminding me that no path is too difficult when walked with the right person.*

Finally, to everyone who, in one way or another, contributed to this journey - thank you. This thesis is as much a product of your support as it is of my efforts, and I am eternally grateful.

Prasanjeet Kaur

ABSTRACT

This thesis explores the transformative potential of peptide biologics in addressing two major medical challenges breast cancer and fungal keratitis through the innovative application of antimicrobial peptides (AMPs) and cell-penetrating peptides (CPPs). By harnessing their unique selectivity, membrane-targeting ability, and low toxicity, this work aims to push the boundaries of conventional therapeutics and offer next-generation treatment strategies.

Part I focuses on a venom-derived AMP, Ltc2a, evaluated for its anticancer efficacy. *In vitro* studies across human cancer cell lines revealed significant cytotoxicity in comparison to normal HEK293T cells. Moreover, the disruption of 3D spheroid integrity by Ltc2a was also observed. The LDH assay and PI staining revealed a membranolytic mode of action of the peptide. Interestingly, *in vivo* analysis in a murine breast cancer model demonstrated remarkable tumour suppression, reduced expression of Ki67 and CD34, and increased apoptosis confirmed through TUNEL assays. The truncated variants of Ltc2a were designed to gain insights into the region responsible for its activity. Interestingly, the truncated variants retained their helical structure but exhibited no cytotoxicity at the tested concentration, suggesting the role of specific amino acids in the activity of peptides. However, the differential uptake of variants in cancer cells vs. normal cells suggests the potential selectivity of peptides, opening avenues for targeted drug delivery. Importantly, histological evaluation of major organs and comprehensive haematological and biochemical analyses confirmed the excellent safety profile of Ltc2a, with no observable systemic toxicity. In parallel, zebrafish toxicity and bioavailability studies validated the peptide's biocompatibility and systemic distribution, supporting its translational potential.

Part II shifts focus to the CPP Tat₂, exploring its peptide membrane interactions and antifungal efficacy. This study demonstrates the successful uptake of Tat₂ across multiple mammalian cell lines, conforming its broad delivery potential. The mechanism of action of Tat₂ revealed concentration dependent uptake with lower concentration favouring endocytosis while higher concentration demonstrating direct penetration. Atomic force microscopy revealed increased membrane roughness following peptide exposure, while FESEM confirmed the absence of gross morphological changes, suggesting a selective, non-disruptive entry mechanism. Molecular dynamics simulations unravelled Tat₂'s preferential interaction with anionic lipid membranes, leading to bilayer thinning and water penetration. Circular dichroism spectroscopy

showed that Tat₂ remains unstructured in lipid environments, which likely contributes to its functional flexibility.

Tat₂ also demonstrated potent antifungal activity against *Fusarium dimerum*, impairing hyphal growth via membrane disruption. It successfully penetrated the corneal epithelium in a rabbit model and resolved fungal keratitis in mice, showing anti-inflammatory properties and no detectable ocular or systemic toxicity.

In conclusion, this work presents two promising peptide candidates Ltc2a for cancer and Tat₂ for fungal infections as powerful, safe, and multifunctional biologics with the potential to revolutionize current treatment paradigms.

सार

यह शोध एंटीमाइक्रोबियल पेप्टाइड्स (एएमपी) और सेल-पेनेट्रेटिंग पेप्टाइड्स (सीपीपी) के अभिनव अनुप्रयोग के माध्यम से दो प्रमुख चिकित्सा चुनौतियों स्तन कैंसर और फंगल केराटाइटिस को संबोधित करने में पेप्टाइड बायोलॉजिक्स की परिवर्तनकारी क्षमता की खोज करता है। उनकी अनूठी चयनात्मकता, झिल्ली-लक्ष्यीकरण क्षमता और कम विषाक्तता का उपयोग करके, इस कार्य का उद्देश्य पारंपरिक चिकित्सा की सीमाओं को आगे बढ़ाना और अगली पीढ़ी की उपचार रणनीतियों की पेशकश करना है।

भाग I एक विष-व्युत्पन्न एएमपी, Ltc2a पर केंद्रित है, जिसका मूल्यांकन इसकी कैंसर विरोधी प्रभावकारिता के लिए किया गया है। मानव कैंसर कोशिका रेखाओं में इन विट्रो अध्ययनों ने सामान्य HEK293T कोशिकाओं की तुलना में महत्वपूर्ण साइटोटॉक्सिसिटी का खुलासा किया। इसके अलावा, Ltc2a द्वारा 3D गोलाकार अखंडता का विघटन भी देखा गया। LDH परख और PI धुंधलापन ने पेप्टाइड की क्रिया के एक मेम्ब्रेनोलिटिक मोड का खुलासा किया। दिलचस्प बात यह है कि म्यूरिन ब्रेस्ट कैंसर मॉडल में इन विवो विश्लेषण ने उल्लेखनीय ट्यूमर दमन, Ki67 और CD34 की अभिव्यक्ति में कमी और TUNEL परख के माध्यम से पुष्टि की गई एपोटोसिस में वृद्धि को प्रदर्शित किया। Ltc2a के काटे गए वेरिएंट को इसकी गतिविधि के लिए जिम्मेदार क्षेत्र में अंतर्दृष्टि प्राप्त करने के लिए डिज़ाइन किया गया था। दिलचस्प बात यह है कि काटे गए वेरिएंट ने अपनी हेलिकल संरचना को बनाए रखा, लेकिन परीक्षण की गई सांद्रता पर कोई साइटोटॉक्सिसिटी नहीं दिखाई, जो पेप्टाइड्स की गतिविधि में विशिष्ट अमीनो एसिड की भूमिका का सुझाव देता है। हालांकि, कैंसर कोशिकाओं बनाम सामान्य कोशिकाओं में वेरिएंट के विभेदक अवशोषण से पेप्टाइड्स की संभावित चयनात्मकता का पता चलता है, जिससे लक्षित दवा वितरण के लिए रास्ते खुलते हैं। महत्वपूर्ण रूप से, प्रमुख अंगों के हिस्टोलॉजिकल मूल्यांकन और व्यापक हेमाटोलॉजिकल और जैव रासायनिक विश्लेषण ने Ltc2a की उत्कृष्ट सुरक्षा प्रोफ़ाइल की पुष्टि की, जिसमें कोई अवलोकन योग्य प्रणालीगत विषाक्तता नहीं थी। समानांतर में, ज़ेब्राफ़िश विषाक्तता और जैवउपलब्धता अध्ययनों ने पेप्टाइड की जैव-संगतता और प्रणालीगत वितरण को मान्य किया, जो इसकी अनुवाद क्षमता का समर्थन करता है।

भाग II सीपीपी टैट2 पर ध्यान केंद्रित करता है, इसकी पेप्टाइड झिल्ली अंतःक्रियाओं और एंटीफंगल प्रभावकारिता की खोज करता है। यह अध्ययन कई स्तनधारी कोशिका रेखाओं में टैट2 के सफल अवशोषण को प्रदर्शित करता है, जो इसकी व्यापक वितरण क्षमता को दर्शाता है। टैट2 की क्रियाविधि ने सांद्रता पर निर्भर अवशोषण को प्रकट किया, जिसमें कम सांद्रता एंडोसाइटोसिस को बढ़ावा देती है जबकि उच्च सांद्रता प्रत्यक्ष प्रवेश को प्रदर्शित करती है। परमाणु बल

माइक्रोस्कोपी ने पेप्टाइड एक्सपोजर के बाद झिल्ली खुरदरापन में वृद्धि का खुलासा किया, जबकि FESEM ने सकल रूपात्मक परिवर्तनों की अनुपस्थिति की पुष्टि की, जो एक चयनात्मक, गैर-विघटनकारी प्रवेश तंत्र का सुझाव देता है। आणविक गतिशीलता सिमुलेशन ने एनायनिक लिपिड झिल्लियों के साथ टैट2 की पसंदीदा अंतःक्रिया को उजागर किया, जिससे द्विपरत पतलापन और पानी का प्रवेश हुआ। सर्कुलर डाइक्रोइज्म स्पेक्ट्रोस्कोपी ने दिखाया कि टैट2 लिपिड वातावरण में असंरचित रहता है, जो संभवतः इसके कार्यात्मक लचीलेपन में योगदान देता है। टैट2 ने फ्यूजेरियम डिमेरम के खिलाफ शक्तिशाली एंटीफंगल गतिविधि का भी प्रदर्शन किया, जो झिल्ली विघटन के माध्यम से हाइफल विकास को बाधित करता है। इसने खरगोश के मॉडल में कॉर्नियल उपकला में सफलतापूर्वक प्रवेश किया और चूहों में फंगल केराटाइटिस को ठीक किया, जिससे सूजन-रोधी गुण दिखे और कोई पता लगाने योग्य नेत्र या प्रणालीगत विषाक्तता नहीं हुई।

निष्कर्ष में, यह कार्य कैंसर के लिए Ltc2a और फंगल संक्रमण के लिए Tat2 जैसे दो आशाजनक पेप्टाइड उम्मीदवारों को शक्तिशाली, सुरक्षित और बहुक्रियाशील जैविक पदार्थों के रूप में प्रस्तुत करता है, जिनमें वर्तमान उपचार प्रतिमानों में क्रांति लाने की क्षमता है।

CONTENTS

	<i>Page No.</i>
CERTIFICATE	i
ACKNOWLEDGEMENTS	ii
ABSTRACT	v
LIST OF FIGURES	ix
LIST OF TABLES	xvi
ABBREVIATIONS	xvii
Chapter 1: Introduction and Objectives	1-23
1.1 Antimicrobial peptides (AMPs)	3
1.2 Classification of AMPs	4
1.2.1 Antiviral Peptides	
1.2.2 Antibacterial Peptides	
1.2.3 Antifungal Peptides (AFPs)	
1.2.4 Antiparasitic peptides	
1.2.5 Antimicrobial peptides as Anticancer peptides (ACPs)	
1.3 Mechanism of action of AMPs	7
1.3.1 Membrane disruption	
1.3.2 Intracellular targeting	
1.3.3 Immune modulation	
1.4 Cell penetrating peptides (CPPs)	10
1.5 Overview of breast cancer	11
1.6 Types of breast cancer	13
1.6.1 Histopathological classification	
1.6.2 Molecular subtypes	
1.7 Therapeutic strategies for Breast cancer	15
1.8 Overview of Fungal keratitis	19
1.9 Therapeutic strategies for fungal keratitis	21
1.10 Objectives	22
Chapter 2: Review of Literature	24-41

2.1 Pathophysiology of breast cancer	26
2.2 Molecular targets of breast cancer	28
2.3 Pathogenesis of fungal keratitis	30
2.4 Conventional treatment vs peptide-based treatments	32
2.5 Application of peptides in different diseases	35
2.5.1 Diabetes mellitus	
2.5.2 Cardiovascular diseases	
2.5.3 Intestinal diseases	
2.5.4 Gastric disease/disorders	
2.5.5 Therapeutic peptides in the treatment of cancer	

Chapter 3: Exploring the anticancer potential of venom-derived peptides 42-82

3.1 Introduction	
3.2 Material and methods	
3.3 Results	
3.3.1 <i>Aim 1: Establishing the anticancer activity of Ltc2a in an in-vitro system</i>	
3.3.2 <i>Aim 2: Truncating Ltc2a to identify the region responsible for its activity</i>	
3.3.3 <i>Aim 3: Validating the anticancer activity of Ltc2a in an in vivo model system of breast cancer</i>	
3.4 Discussion	

Chapter 4: Assessing the therapeutic potential of Tat₂ peptide 83-122 against fungal keratitis

4.1 Introduction	
4.2 Material and methods	
4.3 Results	
4.3.1 <i>Aim 1: Understanding the behaviour of Tat₂ in different membrane systems</i>	
4.3.2 <i>Aim 2: Establishing the anti-fungal activity of Tat₂ in an in-vivo model of fungal keratitis</i>	
4.4 Discussion	

SUMMARY	123-125
REFERENCES	126-171
APPENDICES	172-183
AUTHOR'S RESUME	184-189

LIST OF FIGURES

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
1.1	Classification of Antimicrobial peptides	4
1.2	Different models of membrane disruption by AMPs	8
1.3	Risk factors of breast cancer	12
1.4	Molecular subtypes of breast cancer	15
1.5	Anatomical barriers of the human eye and current routes of drug administration	19
1.6	Risk factors of fungal keratitis	20
2.1	Pathophysiology of breast cancer	27
2.2	Molecular mechanism of breast cancer	29
2.3	Pathophysiology of fungal keratitis	31
3.1	Cell viability at varying concentrations of a. Ltc2a on different cell lines after 24 h treatment and b. Ltc2a after 1 h peptide treatment on MDA-MB-231 cells by MTT assay	55
3.2	Colony formation assay to assess the effect of peptide a. Representative images of 6-well plate showing different levels of colony formation of Ltc2a treated MDA-MB-231 cells, b. Quantification of colony area by ImageJ plugin ColonyArea	56

3.3	Epifluorescence microscopy to assess uptake of Ltc2a in MDA-MB-231 cells. Representative bright-field and FITC-fluorescent images (scale bar 100 μ m)	57
3.4	Membrane damaging effect of Ltc2a on MDA-MB-231 cells. Representative bright-field and PI red fluorescent images after 1h of peptide treatment at varying concentrations (scale bar 100 μ m)	58
3.5	Effect of Ltc2a on cell membrane integrity observed by FESEM at different magnifications: a. 500, b. 2K, c. 5K and d. 20K in A. MDA-MB-231 and B. HEK 293T cells after 1 h treatment	59
3.6	A. Survival rate of zebrafish embryos B. Hatching rate of zebrafish embryos after exposure to different concentrations of Ltc2a at 3 dpf for 24 hrs	60
3.7	CLSM images of zebrafish larvae (lateral view) with or without Ltc2a treatment at 4 dpf after 24 h exposure to the peptide to check more generalized bio-distribution. Panel A1-A3 and B1- B3 were acquired at 2.5x magnification (scale bar 500 μ m), and C1-C3 were acquired at 10x magnification (scale bar 100 μ m)	61

3.8	A. Structures along with helical wheel plot and B & C. Secondary structure profile in aqueous and membranous environment, respectively of a. Ltc2a, b. N-terminal, c. mutated N-terminal and d. C-terminal. Helical wheel diagrams were plotted with Heliquist, and the structure of peptides was plotted using Visual Molecular Dynamics (VMD). In Heliquist, the colour coding for residues is yellow for hydrophobic, purple for serine, blue for charged residues, light blue for histidine and grey for small residues. The arrow represents the hydrophobic moment	63
3.9	A. Distance between the centre of mass (COM) of peptide and lipid phosphate centres as a function of time. B. Density profile of peptides and lipid head groups. C. RDF of peptides with respect to a. lipid phosphate group b. choline and c. serine	65
3.10	Cell viability at varying concentrations of Ltc2a variants on a. HCT 116 and b. MDA-MB-231 after 24 h treatment by MTT assay	66
3.11	CD Spectroscopy studies to assess the secondary structure of A. N-terminal, B. mutated N-terminal and C. C-terminal in different environment conditions	67
3.12	Flow cytometry to assess the uptake of A. N-terminal B. mutated N-terminal and C. C-terminal peptide in MDA-MB-231 and HEK 293T cells. a, b and c represent untreated, 10 μ M and 20 μ M of peptide concentrations, respectively	68

3.13	Viability of 4T1 cells at varying concentrations of Ltc2a and doxorubicin after A. 1 h and B. 24 h treatment by MTT assay and C. Bright field images of tumour spheroids after 24 and 48h treatment with different concentrations of Ltc2a (Scale bar 200 μ m), D. Changes in spheroid diameter after treatment and E. Cell viability after 48h of treatment	69
3.14	A. Membrane damage after Ltc2a treatment using LDH assay and B. Ltc2a induced apoptotic cell death in 4T1 cells. 4T1 cells were treated with different concentrations of Ltc2a for 1 h. Cells were harvested for annexin V/PI binding and analyzed by flow cytometry.	70
3.15	Representative images of A. Morphological changes in the tumour after treatment in mice B. Excised tumour from mice exhibiting reduction in size after treatment and C&D. Reduction in tumour volume and weight, respectively	72
3.16	Weight of organs in normal and tumour-induced mice A. weight of spleen, B. weight of kidneys, C. weight of liver, D. weight of lungs and E. effect of treatment on body weight	73
3.17	H&E staining images of mice organs from each group. The scale bar represents 100 μ m	74
3.18	H&E, Ki67 and CD34 staining images of tumour from each group. The scale bar represents 100 μ m. D&E. Quantification of CD34 and Ki67 using ImageJ	76
3.19	The effect of Ltc2a treatment on the tumor as revealed by TUNEL assay	79

4.1	Bright field and fluorescence images of different cell lines showing peptide internalization (Scale bar is 100 μ m)	95
4.2	Figure 4.2. Evaluation of Tat ₂ peptide uptake and internalization mechanism in MDA-MB-231 and HEK 293T cells using flow cytometry. (A, B): Representative scatter plots showing uptake of FITC-labeled Ta ₂ peptide in MDA-MB-231 cells at 37 °C (A) and 4 °C (B). (C, D): Corresponding scatter plots for HEK 293T cells at 37 °C (C) and 4 °C (D). In all plots, ‘a’, ‘b’, and ‘c’ denote untreated (UT), 1 μ M, and 5 μ M of peptide treated cells, respectively. (E): Histogram showing average mean fluorescence intensity (MFI) values at 1, 5, and 15 μ M peptide concentration in MDA-MB-231 and HEK293T cells. (F) Histogram showing average MFI in MDA-MB-231 and HEK293T cells at 37 °C and 4 °C, to assess temperature dependent uptake.	96
4.3	Effect of Tat ₂ on cell membrane integrity observed by A. FESEM at different magnifications (500, 1K, 2K and 20K) and tumour cell topography revealed by AFM. B. Representative AFM images and 3D projections of MDA-MB-231 cells. (a) Untreated cells. (b) Cells treated with 10 μ M of Tat ₂ . (c) Cells treated with 20 μ M of Tat ₂ for 1h. C. Cell membrane roughness evaluation of cells	98
4.4	CD spectroscopy to assess the secondary structure of the peptide in the presence of liposomes of different composition at different time points (A, B, C) and temperatures (D, E, F) G. sonicated and non-sonicated DPPC and H. Different environment conditions	100

4.5	Effect of Tat ₂ on the surface charge density of A. MDA-MB-231 cells, B. HEK 293T cells, C. liposomes and DSC thermograms of Tat ₂ in the presence of D. DPPC, E. DPPG, F. DPPC: DPPG liposomes	102
4.6	A. Representative images of the trajectory of A. a. DPPC b. DPPG c. DPPC: DPPG; B. Distance of Tat ₂ with the membrane centre and C. H-bonds (Blue represents DPPG, and orange DPPC, and red DPPC: DPPG).	104
4.7	Effect on bilayer thickness on Tat ₂ surface adsorption	105
4.8	A. Secondary structure profile B. Partial density plots showing the average localization of Tat ₂ with bilayer components	106
4.9	A. Free energy profiles of Tat ₂ with DPPC (blue), DPPG (red) and DPPC-DPPG (green) bilayers B. Snapshots of the peptide at different locations in the a. DPPC b. DPPG and c. DPPC: DPPG membrane showing pore formation	107
4.10	Fluorescence images showing internalization in peptide-treated F. dimerum hyphae. Top panel represents Differential Interference Contrast (DIC) images of the respective fluorescent images in the bottom panel. Scale 100 μM	108
4.11	Cell-penetrating activity of peptides in F. dimerum: A and B, Images obtained by CLSM and epifluorescence microscopy for uptake of peptides in spores and hyphae respectively; In A and B, DIC images are in inset with corresponding fluorescent images; a, a', No peptide treatment, b,b' FITC-dextran at 10 μM, c,c' FITC-Tat ₂ at 20 μM; Scale bars-2 and 100 μm for A and B; C, Flow cytometry analysis of uptake in spores.	109

-
- 4.12 Figure 4.12. Fluorometric results of trans-epithelial penetration of A. Tat₂ after 1 h of topical application in the left cornea with intact epithelium. Statistical significance was calculated using Mann Whitney U test at a 5% significance level. (*) and (**) represent significant uptake with a p-value < 0.05 and < 0.01 respectively. 111
- 4.13 Effect of PBS, 5% natamycin suspension and Tat₂ on grade reduction and cumulative clinical outcome before and after treatment. A. Representative images of the degree reduction in each group. B. & C. Cumulative clinical scores of Tat₂ for time point 1 and time point 2, respectively. Scoring was done based on grades (Grade 0 has a score of 0, Grade 1 has a score of 1, Grade 2 has a score of 2, Grade 3 has a score of 3, and Grade 4 has a score of 4). P values were calculated using the Wilcoxon sign test at a significance level of 0.05. (*) represents a significant decrease with a p-value less than 0.05 113
- 4.14 Serum levels of IL-6 after treatment with PBS, 5% Natamycin suspension (marketed), and Tat₂. A. IL-6 serum levels post 3-day treatment and B. represents IL-6 levels post 6-day treatment. Statistical significance was calculated using Mann Whitney U test at a 0.05 significance level. (**) represents a significant reduction in cytokine levels with a p-value < 0.019 116
- 4.15 Representative images of H&E-stained mice corneal sections from various grades of fungal keratitis: a. Arrowheads represent infiltrated immune cells, b. areas in corneal epithelium devoid of cells, c. thinner epithelium in Grade 2 infection, d. distinctively breached epithelium in Grade 3 infection, e. Increased immune cells near defective epithelium and f. completely eroded epithelium in Grade 4 infection. Scale bar 50 μ M. 117
-

LIST OF TABLES

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
1.1	Classification of breast cancer based on histological types and grades	14
1.2	Therapeutic options for breast cancer management	17
3.1	List of peptides used in the study and their sequences	46
3.2	A. Haematological analysis of Balb/c mice without tumour and with tumour after treatment and B. Biochemical analysis of Balb/c mice without tumour and with tumour after treatment	75
4.1	Peptide used in the study and their MICs against F.dimerum	108
4.2	Reduction in clinical scores after 3 days of treatment	114
4.3	Reduction in clinical scores after 3 days of treatment	114

ABBREVIATIONS

ACPs	Anticancer Peptides
ACE	Angiotensin Converting Enzyme
AFM	Atomic Force Microscopy
AFPs	Antifungal Peptides
AGS	Adenocarcinoma cell
ALBD	Albumin
ALPU	Alkaline phosphatase
APD3	Antimicrobial Peptide Database
AMCase	Acidic Mammalian Chitinase
AMPs	Antimicrobial Peptides
ATPase	Adenosine triphosphatase
BC	Breast Cancer
BD	<i>Becton Dickinson</i>
BIT	Bilirubin
BMI	Basal Metabolic Index
BNP	Brain Natriuretic Peptide
BRCA	Breast Cancer gene
CA	Calcium
CAGR	Compound Annual Growth Rate
CAR T-cell	Chimeric Antigen Receptor T-cell
CBA	Cytometric Bead Array

CD	Circular Dichroism
CDK4/6	Cyclin-dependent kinase 4 and 6
CFU	Colony Forming Unit
CHARMM-GUI	Chemistry at Harvard Macromolecular Mechanics- Graphical User Interface
CLRs	C-type lectin Receptors
CLSM	Confocal Laser Scanning Microscopy
CNP	C-type Natriuretic peptide
COM	Centre of mass
CPPs	Cell Penetrating Peptides
CPCSEA	Control and Supervision of Experiments on Animals Guidelines
CRENZ	Creatinine
CRF	Central Adrenocorticotropin-releasing Factor
DAB	3,3'-diaminobenzidine
DAPI	4,6-diamino-2-phenylindole
DCIS	Ductal Carcinoma <i>in situ</i>
DIC	Differential Interference Contrast
DLS	Dynamic Light Scattering
DMC1	Disruption of Meiotic Control
DMEM	Dulbecco's Modified Eagle Medium
DMPC	1,2 Dimyristoyl Glycero 3 Phosphorylcholine
DMPG	1,2-Dimyristoyl-sn-glycero-3-phosphoglycerol, sodium salt

DMSO	Dimethyl sulfoxide
DPPC	1,2-Dipalmitoylphosphatidylcholine
DPPG	1,2-Dipalmitoyl-sn-glycero-3-phosphoglycerol
DPX	Dibutylphthalate Polystyrene Xylene
DNA	Deoxyribonucleic Acid
DOPC	1,2-Dioleoyl-sn-glycero-3-phosphocholine
DOPS	1,2-dioleoyl-sn-glycero-3-phospho-L-serine
Dpf	days post-fertilization
DSC	Differential Scanning Calorimeter
<i>E.coli</i>	<i>Escherechia coli</i>
EDTA	Ethylenediamine tetraacetic acid
EGF	Epidermal growth factor
EGFR	Epidermal Growth Factor Receptor
EO	Eosinophils
ER α	Estrogen Receptor Alpha
ERBB2	v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
FACS	Fluorescence-activated cell sorting
FDA	Food and Drug Administration
FESEM	Field Emission Scanning Electron Microscopy
FITC	Fluoroscein Isothiocyanate
<i>F.dimerum</i>	<i>Fusarium dimerum</i>
GAGs	Glycosaminoglycans

GLP	Glucagon-like peptide
GR	Granulocytes
GROMACS	GRoningen MACHine for Chemical Simulations
H&E	Hematoxylin & Eosin
Hb	Haemoglobin
HCl	Hydrochloric acid
HCT	Hematocrit
HER2	Human epidermal growth factor receptor 2
HIV	Human Immunodeficiency Viruses
Hp _f	hours post-fertilization
HPLC	High Performance Liquid Chromatography
HRP	<i>horseradish peroxidase</i>
HSV	Herpes Simplex Virus
IAEC	Institutional Animal Ethics Committee
IARC	International Agency for Research on Cancer
IBC	Inflammatory Breast Cancer
IBD	Inflammatory Bowel Disease
IDC	Invasive Ductal Carcinoma
IHC	Immunohistochemistry
IL-1 β	Interleukin-1 β
ILC	Invasive Lobular Carcinoma
I-TASSER	Iterative Threading ASSEmbly Refinement
LCIS	Lobular Carcinoma <i>in situ</i>

LDH	Lactate dehydrogenase
LINCS	Linear Constraint Solver
LUVs	Large Unilamellar Vesicles
LY	Lymphocytes
MAPs	Membrane-active peptides
MCV	Mean Corpuscular Volume
MCH	Mean Corpuscular Haemoglobin
MCHC	Mean Corpuscular Haemoglobin Concentration
MD	Molecular Dynamic
MFI	Mean Fluorescence Intensity
miRNA	Micro ribonucleic acid
MHC	Major Histocompatibility Complex
MIC	Minimum Inhibitory Concentration
MO	Monocytes
MPV	Mean Platelet Volume
mRNA	messenger RNA
MRE	Mean Residual Ellipticity
mTORC1	Mammalian Target of Rapamycin Complex 1
MTT	3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide
NIB	National Institute of Biologicals
NOD	Nucleotide-binding Oligomerisation domain
NLRs	NOD-like receptors
NPs	Natriuretic Peptides

NPR	Natriuretic Peptide Receptor
NPT	Nose-Hoover Piston Thermostat
NTA	Nanoparticle Tracking Analysis
NVT	Nose-Hoover thermostat with volume and temperature
PARP	Poly (ADP-ribose) polymerase
PBS	Phosphate Buffer Saline
PCT	Procalcitonin
PD-1	Programmed Cell Death Protein 1
PDA	Potato Dextrose Agar
PDB	Potato Dextrose Broth
PD-L1	Programmed Cell Death Ligand 1
PDW	Platelet Distribution Width
PET	Positron emission tomography
PG	Phosphatidylglycerol
PI	Phosphatidylinositol
PI3K	Phosphoinositide 3-kinase
PLT	Platelets
PMAP-23	Porcine Myeloid Antimicrobial Peptide-23
PME	Particle Mesh Ewald
PNPs	Pexiganan Nanoparticles
PR	Progesterone Receptor
PRRs	Pattern Recognition Receptors
PR	Proline-arginine

PrAMP	Proline-rich Antimicrobial Peptide
PRO	Protein
PS	Phosphatidylserine
PTU	Phenylthiourea
QCM-D	Quartz crystal microbalance with dissipation monitoring
RAAS	Renin-Angiotensin-Aldosterone System
RANKL	Receptor activator of nuclear factor-Kb, its ligand
RBC	Red Blood Cell
RDF	Radial Distribution Function
RDWCV	Red Cell Distribution Width-coefficient of Variation
RDWSD	Red Cell Distribution Width Standard Deviation
RNA	Ribonucleic Acid
ROS	Reactive Oxygen Species
RPE	Retinal Pigment Epithelium
RPMI	Roswell Park Memorial Institute
RT	Room temperature
SBS	Short Bowel Syndrome
SDS	Sodium Dodecyl Sulphate
SGPTD	Serum Glutamic Pyruvic Transaminase
SGOTD	Serum Glutamic Oxaloacetic Transaminase
siRNA	small interfering RNA
SPECT	Single-photon emission computed tomography
T2DM	Type-2 Diabetes Mellitus

Tat	Trans-activator of transcription
TBS	Tris-buffered saline
TFE	2,2,2-trifluoroethanol
TIP3P	transferable intermolecular potential with 3 points
TME	Tumour Microenvironment
TNBC	Triple-negative Breast Cancer
TLRs	Toll-like Receptors
TST	Topical-Systemic-Targeted
TUNEL	Terminal deoxynucleotidyl transferase dUTP-mediated nick-end labelling
UA	Uric acid
USD	United States Dollar
USFDA	U.S. Food and Drug Administration
VMD	Visual Molecular Dynamics
VPs	Venom peptides
WBC	White Blood Cell
WHO	World Health Organization